Dan Williams, CEO of SynaptixBio, explains the science behind antisense oligonucleotides (ASOs) and the challenges and opportunities in using them to tackle rare diseases such as H-ABC. Gene silencing’ is a term used to describe the process of stopping a specific gene from making its associated protein. It is different from gene editing in that […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
